Clinical researchers at VCU Massey Cancer Center have successfully completed a phase 1 clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a phase 2 clinical trial to test the safety and effectiveness of the new therapy.
Virginia Commonwealth University Massey Cancer Center Senior Analyst J. Brian Cassel, Ph.D., was recently named a Fulbright Scholar by the United States Department of State and the J. William Fulbright Foreign Scholarship Board. Cassel will depart in early 2012 for London, where for six months he will collaborate with researchers at the King's College London Cicely Saunders Institute to measure the economic impact of end-of-life care in the U.K. and U.S.
At a celebration event today, Gov. Bob McDonnell ceremonially presented a check representing $5 million in state appropriations for fiscal year 2012 to Virginia Commonwealth University Massey Cancer Center. The funding was approved by the General Assembly this winter when the body accepted the governor's budget amendment to provide the additional resources for the center. The $5 million allocation will help Massey to expand and strengthen its research as it works toward achieving National Cancer Institute (NCI) Comprehensive status, the highest level of distinction for a cancer center. Comprehensive status would make Massey the only facility in Virginia with such a designation, and one of only 40 nationally.
Physicians at Virginia Commonwealth University Massey Cancer Center were reported as “Top Docs” in Richmond Magazine’s April 2011 issue. Honored with this recognition were 24 of Massey’s doctors. These selections were the result of a survey that asked Richmond-area physicians whom they would recommend in a range of specialties. Several of Massey’s doctors appeared in more than one category.
Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body’s immune system that can predict a breast cancer patient’s risk of cancer recurrence. This breakthrough may lead to new genetic testing that further personalizes breast cancer care.